Calvin Prof/Alum Release Research Results

From: Phil deHaan (dehp@calvin.edu)
Date: Thu Jul 18 2002 - 10:38:33 EDT

  • Next message: Phil deHaan: "Calvin Announces New Development Officer"

    July 18, 2002 == FOR IMMEDIATE RELEASE

    A cooperative research project between Calvin College and the Spectrum Health
    Flow Cytometry Laboratory has confirmed the benefits of a drug used to treat
    osteoarthritis, a degenerative disease that affects 90% of people over the age
    of 65.

    Calvin biology professor David DeHeer and 2001 Calvin graduate Kyle Sheehan
    have spent the last three years researching the reasons why a substance called
    hyaluronic acid helps relieve the pain of osteoarthritis in people who are not
    helped by such typical anti-inflammatories as ibuprofen. Hyaluronic acid is
    injected right into the joint, typically the knee joint, in a physician's office
    and usually given once a week for five weeks. Its benefits, reduced pain and
    inflamation, last anywhere from six to nine months.

    But some physicians and researchers have doubted the worth of hyaluronic acid,
    which has been used in Europe to treat osteoarthritis since 1987. It's been
    called "goo," in not all-together flattering terms by some researchers. And
    DeHeer himself admits: "It's a long, simple, rather unexciting molecule. It's
    basically repeating sugar units."

    But, despite its simplicity, what DeHeer and Sheehan discovered over the last
    three years is that hyaluronic acid, a natural chemical found in the body in
    particularly high amounts in joint tissue, is an incredibly effective
    anti-inflammatory agent in and around the human knee joint (and non-human joints
    too as evidenced by years of use on race horses).

    This summer they are reporting their findings in papers for three different
    medical journals, including the Journal of Biological Chemistry and the Journal
    of Orthopaedic Research.

    What they'll describe in those papers is their conclusion and how they got to
    it.

    Their conclusion is simple: hyaluronic acid works. But there's more to how it
    works than meets the eye. The drug is injected into the synovial sac, which
    protects the joint and also secretes the synovial fluid, which oils the joint.
    But the half life of the acid is 24 hours, so after about a week the typical
    injection of two millilitres has disappeared. Yet it continues to work. What
    DeHeer and Sheehan hoped to figure out was how. What they discovered is that
    the acid, before it disappears, interacts with a cell called a macrophage.
    Macrophages produce inflammation.

    "Hyaluronic acid," says Sheehan, "basically tells the macrophages to be quiet,
    calm down, to die. Fewer macrophages means less inflammation." In fact Sheehan
    and DeHeer found that hyaluronic acid will eliminate about 99% of the macrophage
    cells. In patients this could contribute to a significant reduction in
    inflammation and pain.

    Their work was done, says DeHeer, at a very basic scientific level. They grew
    macrophage cell cultures. And they studied the impact of clinical preparations
    of hyaluronic acid, which they purchased from the two major manufacturers, on
    those cell cultures, using a sophisticated piece of equipment at Spectrum Health
    called a flow cytometer. The results, they say, were dramatic. Macrophage cell
    cultures treated with the acid were decimated. Those not treated thrived.

    "The result," says DeHeer, "is that macrophage cells behave like they do in a
    person without osteoarthritis. There are lots of big molecules of hyaluronic
    acid, but hardly any macrophage cells. Thus a reduction in inflammation and a
    reduction in pain. This 'unexciting' molecule has a very exciting role in the
    knee joint."

    Contact David DeHeer at 616-957-6083 or dehe@calvin.edu

    -end-



    This archive was generated by hypermail 2b29 : Thu Jul 18 2002 - 10:38:36 EDT